Jazz Pharma's Rylaze Scores FDA Approval For Blood Cancer

  • The FDA has approved Jazz Pharmaceuticals plc JAZZ Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in pediatric and adult patients.
  • The approval covers the use of Rylaze as a component of a multi-agent chemotherapeutic regimen in patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase.
  • The company expects Rylaze will be commercially available in mid-July. 
  • Price Action: JAZZ closed at $177.64 on Wednesday.
Loading...
Loading...
JAZZ Logo
JAZZJazz Pharmaceuticals PLC
$110.540.04%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
43.07
Growth
Not Available
Quality
55.87
Value
31.73
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...